June 30th 2025
A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
February 26th 2025"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC
February 20th 2025Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
December 18th 2024“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.